Clinical Trial

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Study acronym: ABC-X
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2017-11-07; most recent amendment 2026-01-29.
Status change: Not Yet Recruiting → Recruiting 2019-09-11
Trial Details
NCT Number NCT03340129
Lead Sponsor Melanoma Institute Australia
Collaborators: Bristol-Myers Squibb
Conditions Melanoma Stage Iv
Enrollment 218 participants
Start Date 2019-08-14
Primary Completion 2026-08 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-02